Arrowhead Pharma Q3 revenue beats estimates

Arrowhead Pharmaceuticals

07/08/2025 21:14

Overview

Arrowhead fiscal Q3 revenue of $27.8 mln beats analyst expectations

Company reports net loss of $175.2 mln, EPS at -$1.26

Advances in pipeline with several candidates in late-stage trials

Result Drivers

SAREPTA MILESTONE - Arrowhead earned $100 mln from Sarepta for meeting enrollment targets in ARO-DM1 study

PIPELINE PROGRESS - Arrowhead has four candidates in pivotal Phase 3 studies, including plozasiran and zodasiran

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$27.77 mln
$23.70 mln (9 Analysts)
Q3 EPS
-$1.26
Q3 Net Income
-$3.41 mln
Q3 Operating Expenses
$193.32 mln
Q3 Operating Income
-$165.55 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Arrowhead Pharmaceuticals Inc is $39.50, about 58.7% above its August 6 closing price of $16.31

Press Release: ID:nBw8dzG8za

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)